Vasopressin and its analogues in severe adult patients with distributed shock: an interpretation of clinical practice guidelines_Chinese Journal of Evidence-Based Medicine

Authors：

ZHU Xingxing ^1,2 , LU Zongqing ^1,2 , HUA Tianfeng ^1,2 ,  YANG Min ^1,2

1. The 2^nd Department of Intensive Care Unit, the Second Affiliated Hospital of Anhui Medical University, Hefei 230601, P.R.China;
2. The Laboratory of Cardiopulmonary Resuscitation and Critical Care Medicine, the Second Affiliated Hospital of Anhui Medical University, Hefei 230601, P.R.China;

Corresponding author：

YANG Min, Email: 512130761@qq.com

Keywords：

Distributed shock; Vasopressin; Catecholamines; Clinical practice guideline; Interpretation

DOI：

10.7507/1672-2531.202003025

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The hemodynamic management of adult patients with distributed shock often includes the use of catecholamines vasoconstrictor drugs. It was unclear whether adding vasopressin or vasopressin analogs to catecholamine therapy was beneficial for the treatment of patients with distributed shock. The Canadian Society of Intensive Care recently updated its clinical practice guideline to provide recommendations for the addition of vasopressin to catecholamine boosters in adults with distributed shock. This paper interprets it to assist domestic doctors for better understanding of the latest progress.

Citation： ZHU Xingxing, LU Zongqing, HUA Tianfeng, YANG Min. Vasopressin and its analogues in severe adult patients with distributed shock: an interpretation of clinical practice guidelines. Chinese Journal of Evidence-Based Medicine, 2020, 20(8): 913-917. doi: 10.7507/1672-2531.202003025 Copy

1.	Ukor IF, Walley KR. Vasopressin in vasodilatory shock. Crit Care Clin, 2019, 35(2): 247-261.
2.	Russell JA. Bench-to-bedside review: Vasopressin in the management of septic shock. Crit Care, 2011, 15(4): 226.
3.	McIntyre WF, Um KJ, Alhazzani W, et al. Association of vasopressin plus catecholamine vasopressors vs catecholamines alone with atrial fibrillation in patients with distributive shock: a systematic review and meta-analysis. JAMA, 2018, 319(18): 1889-1900.
4.	Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, et al. Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: the VANCS randomized controlled trial. Anesthesiology, 2017, 126(1): 85-93.
5.	Xiao X, Zhang J, Wang Y, et al. Effects of terlipressin on patients with sepsis via improving tissue blood flow. J Surg Res, 2016, 200(1): 274-282.
6.	Hammond DA, Ficek OA, Painter JT, et al. Prospective open-label trial of early concomitant vasopressin and norepinephrine therapy versus initial norepinephrine monotherapy in septic shock. Pharmacotherapy, 2018, 38(5): 531-538.
7.	Honarmand K, Um KJ, Belley-Côté EP, et al. Canadian critical care society clinical practice guideline: the use of vasopressin and vasopressin analogues in critically ill adults with distributive shock. Can J Anaesth, 2020, 67(3): 369-376.
8.	Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ, 2004, 328(7454): 1490.
9.	Barzegar E, Ahmadi A, Mousavi S, et al. The therapeutic role of vasopressin on improving lactate clearance during and after vasogenic shock: microcirculation, is it the black box? Acta Med Iran, 2016, 54(1): 15-23.
10.	Dünser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation, 2003, 107(18): 2313-2319.
11.	Hajjar LA, Zambolim C, Belletti A, et al. Vasopressin versus norepinephrine for the management of septic shock in cancer patients: the vancs ii randomized clinical trial. Crit Care Med, 2019, 47(12): 1743-1750.
12.	Patel BM, Chittock DR, Russell JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology, 2002, 96(3): 576-582.
13.	Lauzier F, Lévy B, Lamarre P, et al. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Med, 2006, 32(11): 1782-1789.
14.	Malay MB, Ashton RC Jr, Landry DW, et al. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma, 1999, 47(4): 699-703.
15.	Morelli A, Ertmer C, Rehberg S, et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care, 2009, 13(4): R130.
16.	Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med, 2008, 358(9): 877-887.
17.	Fonseca-Ruiz N, Lemos Cano A, Ortiz Carmona DP, et al. Uso de vasopresina en pacientes con choque séptico refractario a catecolaminas (Spanish). Acta Colombiana de Cuidado Intensivo, 2013, 13(2): 114-123.
18.	Oliveira S, Dessa F, Rocha C, et al. Early vasopressin application in shock study. Crit Care, 2014, 18(S1): 158.
19.	Abdullah MH, Saleh SM, Morad WS. Terlipressin versus norepinephrine to counteract intraoperative paracentesis induced refractory hypotension in cirrhotic patients. Egypt J Anaes, 2012, 28(1): 29-35.
20.	Acevedo JG, Fernandez J, Escorsell A, et al. Clinical efficacy and safety of terlipressin administration in cirrhotic patients with septic shock. J Hepatol, 2009, 50: S73.
21.	Albanèse J, Leone M, Delmas A, et al. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med, 2005, 33(9): 1897-1902.
22.	陈志, 周萍, 卢院华, 等. 去甲肾上腺素与特利加压素对ARDS合并感染性休克患者影响的比较: 一项前瞻性单盲随机对照研究. 中华危重病急救医学, 2017, 29(2): 111-116.
23.	Choudhury A, Kedarisetty CK, Vashishtha C, et al. A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock. Liver Int, 2017, 37(4): 552-561.
24.	Hua F, Wang X, Zhu L. Terlipressin decreases vascular endothelial growth factor expression and improves oxygenation in patients with acute respiratory distress syndrome and shock. J Emerg Med, 2013, 44(2): 434-439.
25.	Svoboda P, Scheer P, Kantorová I, et al. Terlipressin in the treatment of late phase catecholamine-resistant septic shock. Hepatogastroenterology, 2012, 59(116): 1043-1047.
26.	Liu ZM, Chen J, Kou Q, et al. Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial. Intensive Care Med, 2018, 44(11): 1816-1825.
27.	Prakash V, Choudhury AK, Sarin SK. Early introduction of a combination of low dose terlipressin and noradrenaline as vasopressors is superior to high dose noradrenaline alone in patients of cirrhosis with septic shock (NCT02468063). Hepatology, 2017: 138A.
28.	Russell JA, Vincent JL, Kjølbye AL, et al. Selepressin, a novel selective vasopressin V. Crit Care, 2017, 21(1): 213.
29.	韩旭东, 孙华, 黄晓英, 等. 垂体后叶素与去甲肾上腺素治疗感染性休克比较的临床研究. 中国危重病急救医学, 2012, 24(1): 33-37.
30.	Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA, 2016, 316(5): 509-518.
31.	Wetterslev M, Haase N, Hassager C, et al. New-onset atrial fibrillation in adult critically ill patients: a scoping review. Intensive Care Med, 2019, 45(7): 928-938.
32.	Kim K, Yang PS, Jang E, et al. Long-term impact of newly diagnosed atrial fibrillation during critical care: a South Korean nationwide cohort study. Chest, 2019, 156(3): 518-528.
33.	Walkey AJ, Wiener RS, Ghobrial JM, et al. Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA, 2011, 306(20): 2248-2254.
34.	Nagendran M, Russell JA, Walley KR, et al. Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials. Intensive Care Med, 2019, 45(6): 844-855.
35.	Reardon DP, DeGrado JR, Anger KE, et al. Early vasopressin reduces incidence of new onset arrhythmias. J Crit Care, 2014, 29(4): 482-485.
36.	Hammond DA, Cullen J, Painter JT, et al. Efficacy and safety of the early addition of vasopressin to norepinephrine in septic shock. J Intensive Care Med, 2019, 34(11-12): 910-916.
37.	Wu JY, Stollings JL, Wheeler AP, et al. Efficacy and outcomes after vasopressin guideline implementation in septic shock. Ann Pharmacother, 2017, 51(1): 13-20.
38.	Bauer SR, Sacha GL, Reddy AJ. Mortality, morbidity, and costs after implementation of a vasopressin guideline in medical intensive care patients with septic shock: an interrupted time series analysis. Ann Pharmacother, 2020, 54(4): 314-321.
39.	Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med, 2017, 45(3): 486-552.
40.	Avni T, Lador A, Lev S, et al. Vasopressors for the treatment of septic shock: systematic review and meta-analysis. PLoS One, 2015, 10(8): e0129305.
41.	Huang P, Guo Y, Li B, et al. Terlipressin versus norepinephrine for septic shock: a systematic review and meta-analysis. Front Pharmacol, 2019, 10: 1492.
42.	Williams MD, Russell JA. Terlipressin or norepinephrine in septic shock: do we have the answer? J Thorac Dis, 2019, 11(Suppl 9): S1270-S1273.
43.	Bredhold BE, Winters SD, Callison JC Jr, et al. Impact of the sequence of norepinephrine and vasopressin discontinuation in patients recovering from septic shock. Hosp Pharm, 2020, 55(1): 26-31.
44.	Wu Z, Zhang S, Xu J, et al. Norepinephrine vs vasopressin: which vasopressor should be discontinued first in septic shock? A meta-analysis. Shock, 2020, 53(1): 50-57.
45.	Hammond DA, Sacha GL, Bissell BD, et al. Effects of norepinephrine and vasopressin discontinuation order in the recovery phase of septic shock: a systematic review and individual patient data meta-analysis. Pharmacotherapy, 2019, 39(5): 544-552.
46.	Lam SW, Barreto EF, Scott R, et al. Cost-effectiveness of second-line vasopressors for the treatment of septic shock. J Crit Care, 2020, 55: 48-55.
47.	Laterre PF, Berry SM, Blemings A, et al. Effect of selepressin vs placebo on ventilator- and vasopressor-free days in patients with septic shock: the SEPSIS-ACT randomized clinical trial. JAMA, 2019, 322(15): 1476-1485.
48.	Kunkes JH, Baker WL, Hammond JA, et al. Vasopressin therapy in cardiac surgery. J Card Surg, 2019, 34(1): 20-27.

1. Ukor IF, Walley KR. Vasopressin in vasodilatory shock. Crit Care Clin, 2019, 35(2): 247-261.
2. Russell JA. Bench-to-bedside review: Vasopressin in the management of septic shock. Crit Care, 2011, 15(4): 226.
3. McIntyre WF, Um KJ, Alhazzani W, et al. Association of vasopressin plus catecholamine vasopressors vs catecholamines alone with atrial fibrillation in patients with distributive shock: a systematic review and meta-analysis. JAMA, 2018, 319(18): 1889-1900.
4. Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, et al. Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: the VANCS randomized controlled trial. Anesthesiology, 2017, 126(1): 85-93.
5. Xiao X, Zhang J, Wang Y, et al. Effects of terlipressin on patients with sepsis via improving tissue blood flow. J Surg Res, 2016, 200(1): 274-282.
6. Hammond DA, Ficek OA, Painter JT, et al. Prospective open-label trial of early concomitant vasopressin and norepinephrine therapy versus initial norepinephrine monotherapy in septic shock. Pharmacotherapy, 2018, 38(5): 531-538.
7. Honarmand K, Um KJ, Belley-Côté EP, et al. Canadian critical care society clinical practice guideline: the use of vasopressin and vasopressin analogues in critically ill adults with distributive shock. Can J Anaesth, 2020, 67(3): 369-376.
8. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ, 2004, 328(7454): 1490.
9. Barzegar E, Ahmadi A, Mousavi S, et al. The therapeutic role of vasopressin on improving lactate clearance during and after vasogenic shock: microcirculation, is it the black box? Acta Med Iran, 2016, 54(1): 15-23.
10. Dünser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation, 2003, 107(18): 2313-2319.
11. Hajjar LA, Zambolim C, Belletti A, et al. Vasopressin versus norepinephrine for the management of septic shock in cancer patients: the vancs ii randomized clinical trial. Crit Care Med, 2019, 47(12): 1743-1750.
12. Patel BM, Chittock DR, Russell JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology, 2002, 96(3): 576-582.
13. Lauzier F, Lévy B, Lamarre P, et al. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Med, 2006, 32(11): 1782-1789.
14. Malay MB, Ashton RC Jr, Landry DW, et al. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma, 1999, 47(4): 699-703.
15. Morelli A, Ertmer C, Rehberg S, et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care, 2009, 13(4): R130.
16. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med, 2008, 358(9): 877-887.
17. Fonseca-Ruiz N, Lemos Cano A, Ortiz Carmona DP, et al. Uso de vasopresina en pacientes con choque séptico refractario a catecolaminas (Spanish). Acta Colombiana de Cuidado Intensivo, 2013, 13(2): 114-123.
18. Oliveira S, Dessa F, Rocha C, et al. Early vasopressin application in shock study. Crit Care, 2014, 18(S1): 158.
19. Abdullah MH, Saleh SM, Morad WS. Terlipressin versus norepinephrine to counteract intraoperative paracentesis induced refractory hypotension in cirrhotic patients. Egypt J Anaes, 2012, 28(1): 29-35.
20. Acevedo JG, Fernandez J, Escorsell A, et al. Clinical efficacy and safety of terlipressin administration in cirrhotic patients with septic shock. J Hepatol, 2009, 50: S73.
21. Albanèse J, Leone M, Delmas A, et al. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med, 2005, 33(9): 1897-1902.
22. 陈志, 周萍, 卢院华, 等. 去甲肾上腺素与特利加压素对ARDS合并感染性休克患者影响的比较: 一项前瞻性单盲随机对照研究. 中华危重病急救医学, 2017, 29(2): 111-116.
23. Choudhury A, Kedarisetty CK, Vashishtha C, et al. A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock. Liver Int, 2017, 37(4): 552-561.
24. Hua F, Wang X, Zhu L. Terlipressin decreases vascular endothelial growth factor expression and improves oxygenation in patients with acute respiratory distress syndrome and shock. J Emerg Med, 2013, 44(2): 434-439.
25. Svoboda P, Scheer P, Kantorová I, et al. Terlipressin in the treatment of late phase catecholamine-resistant septic shock. Hepatogastroenterology, 2012, 59(116): 1043-1047.
26. Liu ZM, Chen J, Kou Q, et al. Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial. Intensive Care Med, 2018, 44(11): 1816-1825.
27. Prakash V, Choudhury AK, Sarin SK. Early introduction of a combination of low dose terlipressin and noradrenaline as vasopressors is superior to high dose noradrenaline alone in patients of cirrhosis with septic shock (NCT02468063). Hepatology, 2017: 138A.
28. Russell JA, Vincent JL, Kjølbye AL, et al. Selepressin, a novel selective vasopressin V. Crit Care, 2017, 21(1): 213.
29. 韩旭东, 孙华, 黄晓英, 等. 垂体后叶素与去甲肾上腺素治疗感染性休克比较的临床研究. 中国危重病急救医学, 2012, 24(1): 33-37.
30. Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA, 2016, 316(5): 509-518.
31. Wetterslev M, Haase N, Hassager C, et al. New-onset atrial fibrillation in adult critically ill patients: a scoping review. Intensive Care Med, 2019, 45(7): 928-938.
32. Kim K, Yang PS, Jang E, et al. Long-term impact of newly diagnosed atrial fibrillation during critical care: a South Korean nationwide cohort study. Chest, 2019, 156(3): 518-528.
33. Walkey AJ, Wiener RS, Ghobrial JM, et al. Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA, 2011, 306(20): 2248-2254.
34. Nagendran M, Russell JA, Walley KR, et al. Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials. Intensive Care Med, 2019, 45(6): 844-855.
35. Reardon DP, DeGrado JR, Anger KE, et al. Early vasopressin reduces incidence of new onset arrhythmias. J Crit Care, 2014, 29(4): 482-485.
36. Hammond DA, Cullen J, Painter JT, et al. Efficacy and safety of the early addition of vasopressin to norepinephrine in septic shock. J Intensive Care Med, 2019, 34(11-12): 910-916.
37. Wu JY, Stollings JL, Wheeler AP, et al. Efficacy and outcomes after vasopressin guideline implementation in septic shock. Ann Pharmacother, 2017, 51(1): 13-20.
38. Bauer SR, Sacha GL, Reddy AJ. Mortality, morbidity, and costs after implementation of a vasopressin guideline in medical intensive care patients with septic shock: an interrupted time series analysis. Ann Pharmacother, 2020, 54(4): 314-321.
39. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med, 2017, 45(3): 486-552.
40. Avni T, Lador A, Lev S, et al. Vasopressors for the treatment of septic shock: systematic review and meta-analysis. PLoS One, 2015, 10(8): e0129305.
41. Huang P, Guo Y, Li B, et al. Terlipressin versus norepinephrine for septic shock: a systematic review and meta-analysis. Front Pharmacol, 2019, 10: 1492.
42. Williams MD, Russell JA. Terlipressin or norepinephrine in septic shock: do we have the answer? J Thorac Dis, 2019, 11(Suppl 9): S1270-S1273.
43. Bredhold BE, Winters SD, Callison JC Jr, et al. Impact of the sequence of norepinephrine and vasopressin discontinuation in patients recovering from septic shock. Hosp Pharm, 2020, 55(1): 26-31.
44. Wu Z, Zhang S, Xu J, et al. Norepinephrine vs vasopressin: which vasopressor should be discontinued first in septic shock? A meta-analysis. Shock, 2020, 53(1): 50-57.
45. Hammond DA, Sacha GL, Bissell BD, et al. Effects of norepinephrine and vasopressin discontinuation order in the recovery phase of septic shock: a systematic review and individual patient data meta-analysis. Pharmacotherapy, 2019, 39(5): 544-552.
46. Lam SW, Barreto EF, Scott R, et al. Cost-effectiveness of second-line vasopressors for the treatment of septic shock. J Crit Care, 2020, 55: 48-55.
47. Laterre PF, Berry SM, Blemings A, et al. Effect of selepressin vs placebo on ventilator- and vasopressor-free days in patients with septic shock: the SEPSIS-ACT randomized clinical trial. JAMA, 2019, 322(15): 1476-1485.
48. Kunkes JH, Baker WL, Hammond JA, et al. Vasopressin therapy in cardiac surgery. J Card Surg, 2019, 34(1): 20-27.

Previous Article
Evidence-based practice guideline on integrative medicine for stroke 2019
Next Article
Preliminary construction of value judgment framework of precision medicine technology

Chinese Journal of Evidence-Based Medicine

Vasopressin and its analogues in severe adult patients with distributed shock: an interpretation of clinical practice guidelines

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content